Breathe Well Live Well
|
Through 2020, the Asthma Drug Market Will Remain Flat Amidst Generic Erosion …
MarketWatch (press release) The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor advisory service entitled Asthma finds that the … |
View full post on asthma – Google News
|
Asthma drug omalizumab cuts treatment needs
Nursing Times Severe persistent allergic asthma sufferers treated with omalizumab have been shown to use far fewer NHS resources than those treated with other drugs. The drug, marketed as Xolair, has also been shown to significantly improve users' health-related … Novartis study shows cost-effectiveness benefits of Xolair |
View full post on asthma – Google News
|
New drug target for asthma and allergies disclosed
HealthJockey.com Allergies like asthma are very common which calls for even more therapeutic alternatives, other the ones used presently. Something known as histamine releasing factor (HRF) molecule is what experts from the La Jolla Institute for Allergy and Immunology … Uncovering Asthma and Allergy Triggers Asthma And Allergies – HRF Molecule Is A Promising Target For Treatment |
View full post on asthma – Google News
|
Boardman pediatric doctor: Don't give Tylenol drug to children with asthma
Youngstown Vindicator An Akron Children's Hospital pediatric physician's stance that children with asthma should not use medicines containing acetaminophen has drawn national attention. Common over-the-counter medicines containing acetaminophen include … |
View full post on asthma – Google News
 Irish Independent |
Only few receiving asthma drug
Insideireland.ie The Asthma Society of Ireland (ASI) has claimed that severe asthma sufferers in some parts of the country do not have access to life-changing treatment. The ASI insists that if the medication needed was divided between the rest of the … More than half asthma sufferers have no access to life-changing treatment |
View full post on asthma – Google News
 Irish Independent |
Many missing out on vital asthma drug
Irish Health Half of people in Ireland with a severe type of asthma cannot access an innovative drug, which could dramatically improve their quality of life, the Asthma Society of Ireland (ASI) has said. A recent study published in the Irish Journal of Medical … Half 'not given severe asthma drug' |
View full post on asthma – Google News
|
How Safe Is Your Asthma Drug? Part One
OpEdNews The popular asthma drugs Symbicort, Advair Diskus, Serevent Diskus, Dulera and Foradil do both and actually warn on their labels that they cause an increased "risk of death from asthma problems." Big Pharma and the FDA have known for years that … |
View full post on asthma – Google News
|
Revalesio Presenting RNS60 Data at ACAAI
Drug Discovery & Development ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5000 members devoted to the specialty of allergy and immunology. In this first in man asthma study, RNS60 demonstrated therapeutic benefit and … |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News
 This is Money |
MARKET REPORT: Skyepharma in a jam over asthma drug
This is Money … was run by its controversial founder Ian Gowrie Smith, who then had a history of over-promising and under-delivering, the City was up in arms after he announced a shock deeply-discounted £35m rights issue to develop Flutiform, its asthma treatment. … SkyePharma's Asthma Treatment Faces European Approval Delay; Shares Fall SkyePharma hit with European delay on Flutiform app SkyePharma lung drug faces European approval delay |
View full post on asthma – Google News